GREENLAND MINES LTD Deferred Federal Income Tax Expense (Benefit)
GREENLAND MINES LTD (GRML) reported Deferred Federal Income Tax Expense (Benefit) of -$257.16 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-17.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2024-04-17
- GREENLAND MINES LTD deferred federal income tax expense (benefit) for fiscal 2023 was -$257.16K.
- GREENLAND MINES LTD deferred federal income tax expense (benefit) for fiscal 2022 was -$33.18K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2023-12-31 | -$257.16K 10-K · filed 2024-04-17 |
| 2022-12-31 | -$33.18K 10-K · filed 2024-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |